MGI PHARMA, INC. (MOGN)'s Aloxi(R) Phase 3 Data for Post Operative Nausea and Vomiting (PONV) Presented at the Annual Meeting of the American Society of Anesthesiologists (ASA)
10/15/2007 12:38:19 PM
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the presentation of results of Study PALO-04-07 at the Annual Meeting of the American Society of Anesthesiologists (ASA). PALO-04-07 is a randomized, multi-center phase 3 clinical trial conducted to evaluate the safety and efficacy of Aloxi® (palonosetron hydrochloride) Injection compared to placebo for the prevention of post-operative nausea and vomiting (PONV) following elective inpatient gynecologic or breast surgery. PALO-04-07, along with PALO-04-06, a randomized, multi-center phase 3 clinical trial conducted to evaluate the safety and efficacy of Aloxi compared to placebo for the prevention of PONV following elective outpatient laparoscopic abdominal or gynecological laparoscopic surgery, served as the basis of a supplemental New Drug Application that was accepted for filing by the Food and Drug Administration on July 9, 2007.
comments powered by